Skip to content

Market explorer

Screen the results we have checked

Search and filter our published results. This is selected coverage, not a screen of every listed stock.

Read the basis before comparing. Revenue is the company's reported revenue line, not a standardised comparable measure. Excise, acquisitions, exceptional items and different reporting periods can change growth. Missing revenue or growth is not zero. Each result below keeps its filing basis and caveats. No live prices, valuation filters or recommendations.

1 matching results out of 156 published entries. 69 have revenue growth available.

Bliss GVS Pharma

+28.22% revenue YoY

Q2 FY2027 · Period ended 30 Sep 2026

Basis: Consolidated, unaudited

Reported revenue (₹ crore, except EPS in ₹/share): 313.37

Read summary and comparison caveats

Bliss GVS Pharma reported consolidated operating revenue of ₹313.37 crore, up 28.22% year on year and 9.73% from June. Owners' profit was ₹52.25 crore, up 91.75% year on year and 4.30% quarter on quarter. Basic EPS was ₹4.92; diluted EPS was ₹4.81.

  • Source: combined standalone/consolidated statement on PDF page 2, notes on page 5 and consolidated limited-review report on pages 7-8. Original ₹ lakh values are divided by 100 for crore; changes use original amounts before rounding. EPS changes use reported per-share values.
  • Year ago is 30 Sep 2025; previous quarter is 30 Jun 2026. Owners' PAT is ₹5,225.22 lakh versus ₹2,725.04 lakh and ₹5,009.74 lakh. Total group PAT is ₹5,334.20 lakh versus ₹2,858.86 lakh and ₹5,137.20 lakh; non-controlling profit is ₹108.98 lakh versus ₹133.82 lakh and ₹127.46 lakh. These bases are not mixed.
  • Consolidated revenue ₹31,336.70 lakh plus other income ₹830.49 lakh less expenses ₹24,657.41 lakh gives PBT ₹7,509.78 lakh. Current tax ₹2,172.35 lakh plus deferred tax ₹74.99 lakh less earlier-year tax credit ₹71.76 lakh gives tax ₹2,175.58 lakh and group PAT ₹5,334.20 lakh. Year-ago deferred tax was a ₹226.64 lakh credit; June was ₹747.82 lakh expense. No tax-normalised profit is estimated.
  • The ₹4,108.61 lakh impairment-provision reversal in note 6(a) belongs to standalone results, not consolidated exceptional income. It lifts standalone PAT to ₹7,356.54 lakh; it is not added to this consolidated owners' PAT. Consolidated exceptional items are nil for all three compared quarters.
  • Current group OCI is a ₹166.25 lakh loss, including foreign-operation translation loss ₹188.67 lakh. Group total comprehensive income ₹5,167.95 lakh is not PAT. Half-year operating cash inflow is ₹3,569.38 lakh versus ₹7,755.21 lakh a year ago; earnings growth is not described as cash-flow growth.
  • Half-year employee expense includes ₹698.82 lakh share-based payments versus ₹314.04 lakh. Note 5 records 541,500 employee-option shares allotted during the half year and another 53,500 after period-end. Closing capital is ₹1,063.30 lakh at ₹1 face value versus ₹1,056.49 lakh a year ago and ₹1,060.56 lakh in June. Basic/diluted EPS are separate and not annualised.
  • Note 7 says Anupam Rasayan India, with the named person acting in concert, acquired 50.07% and became holding company/promoter from 28 Sep 2026; the board was reconstituted. The company says the change in control has no impact on these quarter/half-year results. No organic-growth claim is inferred.
  • The consolidated review relies on other auditors for three subsidiaries and three step-down subsidiaries, and includes one unreviewed step-down subsidiary with ₹0.89 lakh assets and nil revenue/PAT, described by management as immaterial. The conclusion is unmodified; limited review is not an audit. Note 3 identifies a single Pharmaceutical and Healthcare operating segment.
  • Selected original-source coverage, not a complete market list. Duplicate filings, board-meeting notices and newspaper copies are not additional results. Raw RSS notice time carries no timezone suffix.

Checked 29 Oct 2026

Open original filing
Read the complete published results desk